Key Takeaways
- Volume-led double-digit growth: General medicines grew 11% underlying volume, specialty surged 37%, and pediatric vaccines stabilised at 15% growth, all driven by volume rather than price.
- Margins hit a new plateau: EBITDA margin improved 370 bps YoY to 30.7%, but management now aims to sustain rather than expand, calling the low-hanging fruit and raw material inefficiencies sorted.
- Adult vaccination is an endurance sport: Shingles awareness campaigns are building an ecosystem that does not yet exist in India; management frames this as a long-distance play with a bouquet of antigens to follow.
- Two oncology assets near launch: Marketing authorisation received for endometrial and ovarian cancer drugs, with launch targeted for end-Q1 or Q2 of next financial year.
- What to watch next quarter: The launch timing of the two oncology assets, whether the specialty respiratory portfolio sustains its month-on-month patient additions, and any signal on how the adult vaccination ecosystem build is converting awareness into clinic-level adoption.
Revenue Growth: Volume, Not Price
- General medicines engine: 11% underlying volume growth with only 3% blended price increase, driven by digital acceleration that increased touch points with consented HCPs beyond face-to-face interactions, plus science-based initiatives like the India Infection Index promoting appropriate antibiotic use.
- Portfolio breadth holds: Most brands delivered a higher-than-market Evolution Index, and even in categories without external traction, market shares were held. 12 brands exceed ₹100 cr each, with some at the top of the Indian Pharmaceutical Market.
- Strategic category focus: Anti-infectives, dermatology, and pain are still seeing high single-digit or double-digit growth, and management argues molecules spanning infancy to geriatric life stages will not go out of relevance.
- MR productivity jump: 27% improvement in 9M FY25 came from redeployment and repurposing of sales teams, with the last optimisation in Q3 of the prior financial year and no further optimisation in the last 12 months.
Akshikar: "we remain absolutely laser focused"
Specialty & Vaccines: The New Growth Platforms
- Specialty respiratory delivering: Nucala (severe eosinophilic asthma) and Trelegy (fastest-growing single-inhalation triple therapy in the Bronco space) both grew month after month, with Q3 highlighted for new patient additions. Both are called out as critical to FY25-26 performance.
- Pediatric vaccines stabilised: The portfolio has regained market share over the last four quarters after the dual shocks of NLEM inclusion and post-COVID clinic footfall declines, maintaining leadership in the self-paid private pediatric vaccine market.
- Adult vaccination build: Shingles awareness campaigns ran across TVCs and social/digital platforms in Q3, aimed at educating consumers on risk factors and prevention. Management is building the vaccination ecosystem in HCP clinics and hospital setups, with a bouquet of adult antigens planned beyond Shingles.
- Successor PCV vaccine: MAPS, the successor to Synflorix, is undergoing clinical trials.
Akshikar: "this is an endurance sport in a country where adult vaccination ecosystems do not exist"
Oncology: Two Launches, One Platform
- Near-term launches: Marketing authorisation received for two assets targeting gynecological malignancies, one for endometrial cancer and one for ovarian cancer. Launch is planned for end-Q1 or latest Q2 of the next financial year.
- Jemperli platform potential: The PD-1 inhibitor Dostarlimab is currently indicated for second-line endometrial cancer, but trials will expand into head and neck, non-small cell lung cancer, and colon cancer, with each indication opening a different revenue stream over time.
- Pipeline beyond the visible: Management referenced 16 global clinical trials in India across hematological malignancies and hepatology, but when asked directly about additional pipeline products or inorganic and in-licensing opportunities, it reiterated existing strategy without confirming new assets beyond those already disclosed.
Margins: Plateau, Not Climb
- The improvement story: EBITDA margin reached 30.7%, up 370 bps YoY, and PAT margin improved 380 bps to 24%. SG&A ratio improved by almost 2% of sales due to efficiency initiatives started roughly two years ago.
- Why the climb stops here: Management stated that low-hanging fruits and raw material price issues have been sorted out, and margins have stabilised over the last couple of quarters. The explicit stance is to sustain, not to forecast further expansion.
- Other expenses phasing: Q3 other expenses were higher due to advertisement and promotional spend phasing and CSR phasing, but year-to-date cumulative other expenses as a percentage of sales remain unchanged.
- Top-quartile positioning: Management noted the company is already in the top quartile of pharma companies for margins, framing the current level as a destination rather than a waypoint.
Akshikar: "I won't really forecast growing up, but I think our effort will be to sustain the margins because being a significant distance that we have travelled and I think where we are today, our entire energy will be to sustain these margins as we go forward."
Unanswered Questions
- Land parcel monetisation: The company continues to hold land parcels including the Bangalore site, but when asked about monetisation plans referenced at the AGM 3-5 years ago, management gave no update on timing or intentions.
- Pipeline depth beyond disclosed assets: When asked whether there are more products in the pipeline or inorganic and in-licensing opportunities beyond Nucala, Trelegy, and the two cancer drugs, management reiterated the existing strategy and global clinical trials but did not confirm additional near-term assets.
- New product introduction appetite: An analyst asked whether the market environment has changed to give confidence for more new product introductions than in the past; management deflected, calling the premise "not completely correct" and referencing the 2014 oncology business without directly answering.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Oncology asset launches | Two products for gynecological malignancies (endometrial cancer, ovarian cancer) | End-Q1 or latest Q2 of next financial year |
| Adult vaccination ecosystem build | Continue investing in building ecosystem so adults above 50 can benefit from Shingles prevention; bouquet of adult antigens to follow | Next 12-18 months |
| Top-line growth ambition | Remain focused on delivering double-digit volume-led growth | Short to medium term |
| Margin trajectory | Effort is to sustain current margins, not to grow them further | Going forward |
| New innovative assets | Oncology assets and other innovative assets coming up | Next 18-24 months |
Key Metrics
| Metric | Q3 FY25 |
|---|---|
| Revenue growth | 18% YoY |
| General medicines underlying volume growth | 11% |
| Specialty portfolio growth | ~37% |
| Pediatric vaccines growth | 15% |
| Total vaccines portfolio growth (including Shingrix) | 15% YoY; 14% for 9 months |
| EBITDA | ₹290 cr, growth of 33% YoY |
| EBITDA margin | 30.7%, improvement of 370 bps YoY |
| SG&A expense ratio | improved by ~2% of sales YoY |
| Profit After Tax growth | 31% YoY |
| PAT margin | 24%, improvement of 380 bps YoY |
| Year-to-date December revenue growth | 10% |
| Year-to-date December profit growth | 30% |
| Year-to-date December EBITDA margin | 30.4%, margin improvement of 450 bps |
| Cash conversion | 100% of profit into cash |
| Blended price increase in GenMed segment | ~3% |
| One-off reduction in employee cost | ₹9 cr, due to lower incentives for some brands |
| Trelegy growth | in excess of 80% on a 12-month or quarterly basis for Q3 |
| Trelegy category size | almost touching ₹100 cr |
| Trelegy market share | 5–5.5% |
| MR productivity improvement | 27% in 9 months of fiscal 25 |
| Brands above ₹100 cr each | 12 |
| Towns covered by sales teams | more than 12,000 |
| Healthcare practitioners newly vaccinating adults | 2,500 |